Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Deerland Enzymes

Deerland Enzymes?uq=kzBhZRuG
1990 FOUNDED
M&A STATUS
PE Growth LATEST DEAL TYPE
2 FINANCING ROUNDS
Description

Developer, formulator and manufacturer of enzyme and probiotic-based dietary supplements. The company is engaged in developing customized enzyme and probiotic-based formulations, collaborating with customers to develop innovative and proprietary formations, which are university and clinically studied branded products. It also provides regulatory support and performs specialty contract manufacturing services including bulk blends, liquids, hard shell capsules and tablets as well as bottling and labeling.

Ownership Status
Acquired/Merged
Financing Status
Private Equity-Backed
Primary Industry
Pharmaceuticals
Other Industries
Drug Discovery
Primary Office
  • 3800 Cobb International Boulevard
  • Kennesaw, GA 30152
  • United States

+1 (800) 000-0000

Deerland Enzymes Valuation and Funding

Deal Type Date Amount Post-Val Valuation/
EBITDA
Debt Status

This information is reserved for PitchBook Platform users. To explore Deerland Enzymes‘s full profile, request access.

Request full access to PitchBook

Deerland Enzymes Executive Team (4)

Name Title Board
Seat
Contact
Info
Scott Ravech Chief Executive Officer
Hilton Dawson Chief Technology Officer
Richard DeSenna Founder
Pierre Fréchette Chairman

Deerland Enzymes Board Members (1)

Name Representing Role Since Contact
Info
000000 00é000000 Deerland Enzymes Chairman 000 0000